CYP27B1 Inhibitors
1 drugsAbout CYP27B1
CYP27B1 is an enzyme crucial for vitamin D metabolism, catalyzing the conversion of 25-hydroxyvitamin D3 into its active form, 1,25-dihydroxyvitamin D3 (calcitriol). This activation is essential for calcium homeostasis, bone health, and immune function.
CYP27B1 is a therapeutic target for conditions with impaired vitamin D activation. Currently, there is no genetic evidence available linking CYP27B1 to specific diseases.
CYP27B1 is targeted by one FDA-approved small molecule drug, RAYALDEE (EIRGEN), indicated for two conditions. EIRGEN is the only company with an approved drug for this target.
Top CYP27B1 Drugs
EIRGEN is the only company with an approved drug targeting CYP27B1.
The lack of competition suggests a high barrier to entry or an unvalidated market.
CYP27B1 Drug Modality Landscape
Modalities
Routes of Administration
Only one approved drug targets CYP27B1, using small molecule modality.
Exploring alternative modalities like biologics could provide a competitive advantage in this space.
CYP27B1 Clinical Trials 11 trials
Phase 1-4 trials started in 2008 or later that test an FDA-approved drug acting on CYP27B1. Source: ClinicalTrials.gov. How we count
Completion by Phase
| Phase | Total | Completed | Stopped | Active | Completion |
|---|---|---|---|---|---|
| Phase 2 | 5 | 4 | 1 | 0 | 80% |
| Phase 3 | 1 | 1 | 0 | 0 | 100% |
| Phase 4 | 5 | 4 | 0 | 1 | 100% |
Top Sponsors
By Modality
Top Conditions
Top Drugs
CYP27B1 Drug Approval Timeline (2016 - 2016)
RAYALDEE was first approved in 2016 and remains the only approved drug.
The absence of recent approvals indicates a potentially saturated market or limited innovation in this area.
Pro Intelligence Preview
Deep insights for drug target analysis
Competitive Landscape
- • 1 companies competing
- • Market share by company
Full Drug Portfolio
- • All 1 approved drugs
- • Approval dates & indications
Genetic Validation
- • Full genetic evidence table
- • Effect sizes & directions
Approval Timeline
- • Full 1-drug timeline
- • First-of-modality markers
Clinical Trials Analysis
- • Sponsors: 9 (2 companies)
- • Completion rates by condition
Full summary • All drugs • Genetic evidence • Trials • Timeline
How We Count Trials
- Trials: phase 1-4 interventional trials on ClinicalTrials.gov that started in 2008 or later and test an FDA-approved drug acting on CYP27B1. A trial counts if an approved drug acting on CYP27B1 is in any arm, including as a comparator, and a trial that tests two such drugs counts once. Trials that test only unapproved drugs are not counted. A trial listed as phase 1/2 counts as phase 1, and phase 2/3 as phase 2.
- Active: recruiting, not yet recruiting, enrolling by invitation, or active and no longer recruiting.
- Completion rate: of the trials that have ended, the share marked Completed rather than Terminated or Withdrawn. Completed means the trial ended as planned; it does not mean the drug worked. Suspended trials are not counted as ended.
- Stopped: terminated or withdrawn. Trials stop for many reasons, including slow enrolment and business decisions, not only safety or efficacy.
- Sponsors: the lead sponsor of each trial. Companies are the sponsors ClinicalTrials.gov classes as industry; the rest are universities, hospitals, cooperative groups, government bodies and individuals.